Trial Profile
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Cetuximab; Valproic acid
- Indications Cancer
- Focus Adverse reactions
- 14 Jun 2023 Planned End Date changed from 31 Mar 2023 to 31 Mar 2024.
- 14 Jun 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Mar 2024.
- 18 Jul 2022 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.